[1]黄斌,俞杨,王自正.噬菌体展示肽库技术在肿瘤诊治研究中的应用[J].国际放射医学核医学杂志,2011,35(4):202-206.[doi:10.3760/cma.j.issn.1673-4114.2011.04.002]
　HUANG Bin,YU Yang,WANG Zi-zheng.Phage display peptide library technology’s application in the diagnosis and therapy of tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):202-206.[doi:10.3760/cma.j.issn.1673-4114.2011.04.002]
点击复制

噬菌体展示肽库技术在肿瘤诊治研究中的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第4期
页码:
202-206
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Phage display peptide library technology’s application in the diagnosis and therapy of tumor
作者:
黄斌;  俞杨;  王自正
南京医科大学附属南京第一医院南京市临床核医学中心, 南京 210006
Author(s):
HUANG Bin;  YU Yang;  WANG Zi-zheng
Nanjing Clinical Nuclear Medicine Center, Nanjing First Hospital to Nanjing Medical University, Nanjing 210006, China
关键词:
肽库; 抗肿瘤联合化疗方案; 放射性核素显像; 放射疗法
Keywords:
Peptide library; Anti neoplastic combined chemotherapy protocols; Radionuclide imaging; Radiotherapy
DOI:
10.3760/cma.j.issn.1673-4114.2011.04.002
摘要:
噬菌体展示肽库技术是将高度多样性的多肽与噬菌体衣壳蛋白融合表达,呈现于噬菌体表面的多肽具有相对独立的空间结构,能与配体结合,从而筛选特异性分子表位,其已成为肿瘤诊治研究的重要手段和有力工具。筛选与肿瘤细胞或血管表面细胞特异结合的多肽作为核素载体,制成探针,可以对肿瘤进行早期诊断和转移灶的定位,还可以进行核素治疗;以多肽为基础的靶向药物,可以弥补化学药物在杀伤肿瘤细胞的同时也损伤正常组织和器官的弊端,使得肿瘤治疗进入一个新时代。
Abstract:
Phage display peptide library technology facilitates displaying peptides of high diversity on the surface of phage coat proteins, which with their independent space structure bind with ligands to screen the specific molecule epitopes. With the development of this technology, it becomes an effective and powerful tool in tumor research. As nuclide carrier, peptides screened from phage display library binding specifically with tumor cells and tumor blood vessels, can be manufactured into a probe for prophase diagnosis of tumor, localization of metastasis and nuclide therapy. Targeting chemotherapy drugs on the basis of peptides greatly lower the risk of killing normal tissue and organs, which impulses entering a new therapy time.

参考文献/References:

[1] Smith GP.Filamentous fusion phage:novel expression vectors that display cloned antigens on the virion surface.Science,1985,228(4705):1315-1317.
[2] Kehoe JW,Kay BK.Filamentous phage display in the new millennium.Chem Rev,2005,105(11):4056-4072.
[3] Pasqualini R,Koivunen E,Ruoslahti E.Alpha v integrins as receptors for tumor targeting by circulating ligands.Nat Biotechnol,1997,15(6):542-546.
[4] Nelson AL,Reichert JM.Development trends for therapeutic antibody fragments.Nat Biotechnol,2009,27(4):331-337.
[5] Reichert JM.Monoclonal antibodies as innovative therapeutics.Curr Pharm Biotechnol,2008,9(6):423-430.
[6] Wiiger MT,Gehrken HB,Fodstad O,et al.A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.Cancer Immunol Immunother,2010,59(11):1665-1674.
[7] Lamoureux F,Trichet V,Chipoy C,et al. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.Expert Rev Anticancer Ther,2007,7(2):169-181.
[8] Scotlandi K,Picci P,Kovar H.Targeted therapies in bone sarcomas.Curr Cancer Drug Targets,2009,9(7):843-853.
[9] Seung-Min L,Gil-Suk Y,Eun-Sang Y,et al.Application of phage display to discovery of tumor-specific homing peptides:developing strategies for therapy and molecular imaging of cancer.Methods Mol Biol,2009,512:355-363.
[10] Jayanna PK,Bedi D,Deinnocentes P,et al.Landscape phage ligands for PC3 prostate carcinoma cells.Protein Eng Des Sel,2010,23(6):423-430.
[11] Enback J,Laakkonen P.Tumour-homing peptides: tools for targeting,imaging and destruction.Biochem Soc Trans,2007,35(Pt 4):780-783,
[12] Dijkgraaf I,Beer AJ,Wester HJ.Application of RGD-containing peptides as imaging probes for alphavbeta3 expression.Front Biosci,2009,14:887-899.
[13] Niu G,Chen X.PET Imaging of Angiogenesis,PET Clin,2009,4(1):17-38.
[14] Sun X,Niu G,Yan Y,et al.Phage display-derived peptides for osteosarcoma imaging,Clin Cancer Res,2010,16(16):4268-4277.
[15] Zhang CL,Wang RF,Zhang L,et al.131I labeling and bioactivity evaluation of a novel RGD dimer targeted to integrin alphavbeta3 receptor.Beijing Da Xue Xue Bao,2011,43(2):295-300.
[16] LeungK.68Ga-1,4,7-triazacyclononane-1,4-7-triacetic acidisothiocyanatobenzyl-c (Arg-Gly-Asp-d-Tyr-Lys)[DB/OL].Bethesda(MD):National Center for Biotechnology Information (US),2011-01-26(2011-04-07).http://www.ncbi.nlm.nih.gov/books/NBK53807.
[17] Liu Z,Shi J,Jia B,et al. Two (90)Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.Mol Pharm,2011,8(2):591-599.
[18] Del Valle L,Enam S,Lassak A,et al.Inaulin-like growth factor I receptor activity in human medulloblastomas.Clin Cancer Res,2002,8(6):1822-1830.
[19] Runnels HA,Arbuckle JA,Bailey KS,et al.Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies.Adv Ther,2010,27(7):458-475.
[20] van Kempen LC,Nelissen JM,Degen WG,et al.Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)ALCAM interaction.J Biol Chem,2001,276(28):25783-25790.
[21] Ofori-Acquah SF,King JA.Activated leukocyte cell adhesion molecule:a new paradox in cancer.Transl Res,2008,151(3):122-128.
[22] Arap W,Pasqualini R,Ruoslahti E.Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.Science,1998,279(5349):377-380.
[23] Vogelstein B,Lane D,Levine AJ.Surfing the p53 network.Nature,2000,408(6810):307-310.
[24] Vousden KH,Lane DP.p53 in health and disease.Nat Rev Mol Cell Biol,2007,8(4):275-283.
[25] Liu M,Li C,Pazgier M,et al.D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.Proc Natl Acad Sci USA,2010,107(32):14321-14326.
[26] Marine JC,Dyer MA,Jochemsen AG.MDMX:from bench to bedside.J Cell Sci,2007,120(Pt 3):371-378.
[27] Momand J,Zambetti GP,Olson DC,et al.The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell,1992,69(7):1237-1245.
[28] Honda R,Tanaka H,Yasuda H.Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.FEBS Lett,1997,420(1):25-27.
[29] de Graaf P,Little NA,Ramos YF,et al.Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2.J Biol Chem,2003,278(40):38315-38324.
[30] Linares LK,Hengstermann A,Ciechanover A,et al.HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.Proc Natl Acad Sci USA,2003,100(21):12009-12014.
[31] Martins CP,Brown-Swigart L,Evan GI.Modeling the therapeutic efficacy of p53 restoration in tumors.Cell,2006,127(7):1323-1334,
[32] Ventura A,Kirsch DG,McLaughlin ME,et al.Restoration of p53 function leads to tumour regression in vivo.Nature,2007,445(7128):661-665.
[33] Xue W,Zender L,Miething C,et al.Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.Nature,2007,445(7128):656-660.
[34] Brown CJ,Lain S,Verma CS.Awakening guardian angels:drugging the p53 pathway.Nat Rev Cancer,2009,9(12):862-873.
[35] Murray JK,Gellman SH.Targeting protein-protein interactions:lessons from p53/MDM2.Biopolymers,2007,88(5):657-686.
[36] Shangary S,Qin D,McEachem D,et al.Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.Proc Natl Acad Sci USA,2008,105(10):3933-3938.
[37] Pazgier M,Liu M,Zou G,et al.Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX,Proc Natl Acad Sci USA,2009,106(12):4665-4670.
[38] Liu M,Pazgier M, U C,et al.A left-handed solution to peptide inhibition of the p53-MDM2 interaction.Angew Chem Int Ed Engl,2010,49(21):3649-3652.

相似文献/References:

[1]李卫红,王浩,周晓靓,等.肿瘤放射治疗增敏剂研究新进展[J].国际放射医学核医学杂志,2013,37(4):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
　LI Wei-hong,WANG Hao,ZHOU Xiao-liang,et al.Radiosensitizers development and the pathways[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
[2]陆光兵,刘丽.125I粒子联合EP方案治疗局部晚期非小细胞肺癌的临床分析[J].国际放射医学核医学杂志,2010,34(2):105.[doi:10.3760/cma.j.issn.1673-4114.2010.02.012]
[3]褚丽萍,王彦,王月英,等.多肽类肺癌显像剂的制备及其初步鉴定[J].国际放射医学核医学杂志,2010,34(3):135.
　CHU Li-ping,WANG Yan,WANG Yue-ying,et al.The preparation and identification of peptide imaging agent of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):135.
[4]俞杨,王自正.噬菌体展示体内筛选技术及其应用进展[J].国际放射医学核医学杂志,2008,32(1):5.
　YU Yang,WANG Zi-zheng.Phage display in vivo selection and its application[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):5.
[5]阳艳丽,王自正.噬菌体展示技术在肿瘤诊断和治疗中的应用[J].国际放射医学核医学杂志,2008,32(2):65.
　YANG Yan-li,WANG Zi-zheng.Application of phage display in diagnosis and therapy of cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):65.

备注/Memo

备注/Memo:
收稿日期:2011-04-16。
通讯作者:王自正(Email:zzwang136@yahoo.com.cn)
更新日期/Last Update: 1900-01-01